| High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe C Nyakutira, D Röshammar, E Chigutsa, P Chonzi, M Ashton, C Nhachi, ... European journal of clinical pharmacology 64, 357-365, 2008 | 231 | 2008 |
| A novel polymorphism in ABCB1 gene, CYP2B6* 6 and sex predict single‐dose efavirenz population pharmacokinetics in Ugandans JK Mukonzo, D Röshammar, P Waako, M Andersson, T Fukasawa, ... British journal of clinical pharmacology 68 (5), 690-699, 2009 | 152 | 2009 |
| Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria SF Hietala, A Bhattarai, M Msellem, D Röshammar, AS Ali, J Strömberg, ... Journal of pharmacokinetics and pharmacodynamics 34, 669-686, 2007 | 56 | 2007 |
| Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria SF Hietala, A Bhattarai, M Msellem, D Röshammar, AS Ali, J Strömberg, ... Journal of pharmacokinetics and pharmacodynamics 34, 669-686, 2007 | 56 | 2007 |
| Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects D Röshammar, TN Hai, S Friberg Hietala, N Van Huong, M Ashton European journal of clinical pharmacology 62, 335-341, 2006 | 54 | 2006 |
| In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype D Rekić, D Röshammar, J Mukonzo, M Ashton British journal of clinical pharmacology 71 (4), 536-543, 2011 | 53 | 2011 |
| HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects JK Mukonzo, S Nanzigu, D Rekić, P Waako, D Röshammar, M Ashton, ... Clinical pharmacokinetics 50, 531-540, 2011 | 38 | 2011 |
| HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects JK Mukonzo, S Nanzigu, D Rekić, P Waako, D Röshammar, M Ashton, ... Clinical pharmacokinetics 50, 531-540, 2011 | 37 | 2011 |
| Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection Y Aoki, D Röshammar, B Hamrén, AC Hooker Journal of pharmacokinetics and pharmacodynamics 44, 581-597, 2017 | 35 | 2017 |
| Bilirubin—a potential marker of drug exposure in atazanavir-based antiretroviral therapy D Rekić, O Clewe, D Röshammar, L Flamholc, A Sönnerborg, ... The AAPS journal 13, 598-605, 2011 | 20 | 2011 |
| Characterisation of population pharmacokinetics and endogenous follicle-stimulating hormone (FSH) levels after multiple dosing of a recombinant human FSH (FE 999049) in healthy … TH Rose, D Röshammar, L Erichsen, L Grundemar, JT Ottesen Drugs in R&D 16, 165-172, 2016 | 19 | 2016 |
| Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. H Ericsson, D Röshammar, M Wollbratt, M Heijer, M Persson, S Ueda, ... International journal of clinical pharmacology and therapeutics 50 (11), 765-777, 2012 | 18 | 2012 |
| Population pharmacokinetic modelling of FE 999049, a recombinant human follicle-stimulating hormone, in healthy women after single ascending doses TH Rose, D Röshammar, L Erichsen, L Grundemar, JT Ottesen Drugs in R&D 16, 173-180, 2016 | 17 | 2016 |
| Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients M Åstrand, C Amilon, D Röshammar, A Himmelmann, DJ Angiolillo, ... British Journal of Clinical Pharmacology 85 (2), 413-421, 2019 | 16 | 2019 |
| Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction D Röshammar, M Bergstrand, T Andersson, RF Storey, B Hamrén International Journal of Clinical Pharmacology and Therapeutics 55 (5), 416, 2017 | 16 | 2017 |
| Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N, N‐dimethyltryptamine–Implications for dose considerations E Eckernäs, C Timmermann, R Carhart‐Harris, D Röshammar, M Ashton Clinical and Translational Science 15 (12), 2928-2937, 2022 | 10 | 2022 |
| Pharmacokinetic modeling and simulation support for age‐and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism D Röshammar, F Huang, M Albisetti, L Bomgaars, E Chalmers, M Luciani, ... Journal of Thrombosis and Haemostasis 19 (5), 1259-1270, 2021 | 9 | 2021 |
| Model based design and analysis of phase II HIV-1 trials D Rekić, D Röshammar, USH Simonsson Journal of pharmacokinetics and pharmacodynamics 40, 487-496, 2013 | 7 | 2013 |
| Exposure‐Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction D Röshammar, J Nyberg, T Andersson, D Stanski, RF Storey, B Hamrén The Journal of Clinical Pharmacology 57 (5), 573-583, 2017 | 6 | 2017 |
| Averaged Model Based Decision Making for Dose Selection Studies Y Aoki, B Hamrén, D Röshammar, AC Hooker Annual Meeting of the Population Approach Group in Europe, 2014 | 5 | 2014 |
